Evidence map›Paper›PMID 34563011›Full record

ReviewClinics and practice2021

Early Diagnosis of Lung Cancer in the United Arab Emirates: Challenges and Strategic Recommendations.

Humaid O Al-Shamsi, Hassan Jaffar, Bassam Mahboub, Faraz Khan, Usama Albastaki, Sayed Hammad, Ashraf Al Zaabi

Abstract readReview
In one paragraph

Review in Clinics and practice, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Humaid O Al-ShamsiDepartment of Oncology, Burjeel Cancer Institute, Burjeel Medical City, Abu Dhabi 111499, United Arab Emirates.ORCID 0000-0003-3819-0500
Hassan JaffarSheikh Khalifa Specialty Hospital, Ras Alkhaima 999041, United Arab Emirates.
Bassam MahboubRashid Hospital, Dubai 111499, United Arab Emirates.
Faraz KhanAmerican Hospital, Dubai 111499, United Arab Emirates.
Usama AlbastakiRashid Hospital, Dubai 111499, United Arab Emirates.
Sayed HammadDubai Hospital, Dubai 111499, United Arab Emirates.ORCID 0000-0001-8829-8654
Ashraf Al ZaabiZayed Military Hospital, Abu Dhabi 111499, United Arab Emirates.

Funding

AstraZeneca FZ LLC
6 · The paper itself

Abstract

In the United Arab Emirates (UAE), lung cancer (LC) was the third leading cause of deaths due to cancer in 2017. Around 80% of the patients in the UAE are diagnosed at a late stage, rendering the treatment less effective in improving survival outcomes. Lack of awareness of disease symptomatology, deficient screening initiatives, misdiagnosis, and delayed referral to the specialist are contributing factors for delayed diagnosis. Effective screening at a primary care setting can be crucial for early diagnosis, referral to specialists, and enhancing patient outcomes. It is important to establish screening and referral guidelines through which each suspected case can be identified and provided timely intervention. Although the international screening and referral pathway framework are comprehensive, several regional barriers need to be addressed before they can be adapted at the national level. A group of LC experts from the UAE deliberated on issues like delayed diagnosis of LC and strategic recommendations for overcoming the challenges. The discussion was based on the review of the published evidence, international and regional guidelines for screening and early diagnosis of LC. Herein, we present a guideline, endorsed by the esteemed panel of experts, for aiding early diagnosis and optimizing the management of LC in the UAE.

Indexed as

lung cancerreferral pathwayscreeningUnited Arab Emirates

Identifiers

PMID34563011
PMCPMC8482116

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.